CGH
AMPH icon

Crossmark Global Holdings’s Amphastar Pharmaceuticals AMPH Stock Holding History

Crossmark Global Holdings’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,300
Closed -$452K – 1279
2024
Q2 		$452K Buy
11,300
+275
+2% +$11.4K 0.01% 879
2024
Q1 		$484K Sell
11,025
-194
-2% -$10K 0.01% 882
2023
Q4 		$694K Sell
11,219
-194
-2% -$10.2K 0.01% 719
2023
Q3 		$548K Buy
11,413
+168
+1% +$9.16K 0.01% 784
2023
Q2 		$684K Sell
11,245
-259
-2% -$11.5K 0.01% 714
2023
Q1 		$432K Sell
11,504
-107
-0.9% -$3.51K 0.01% 892
2022
Q4 		$325K Buy
11,611
+330
+3% +$9.58K 0.01% 986
2022
Q3 		$317K Buy
11,281
+129
+1% +$4.21K 0.01% 968
2022
Q2 		$387K Buy
+11,152
New +$398K 0.01% 924

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Crossmark Global Holdings's AMPH Position: Q3 2024 in Review

Crossmark Global Holdings sold out of Amphastar Pharmaceuticals (AMPH) in Q3 2024, closing a stake of 11,300 shares — an estimated $452K sold.

Crossmark Global Holdings first reported a position in AMPH in Q2 2022 and held it in 9 quarters. The position peaked at $694K in Q4 2023. 279 funds tracked by Wall St. Rank hold AMPH as of Q3 2024.

  • Crossmark Global Holdings reported no remaining Amphastar Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Crossmark Global Holdings sold 11,300 Amphastar Pharmaceuticals shares in Q3 2024, an estimated $452K.
  • Crossmark Global Holdings first reported a position in Amphastar Pharmaceuticals in Q2 2022 and held it in 9 quarters.
  • Crossmark Global Holdings's Amphastar Pharmaceuticals position peaked at $694K in Q4 2023.
  • 279 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2024.

Based on Crossmark Global Holdings's 13F filing for Q3 2024, filed 4 Nov 2024.